Enzyme is constantly adding new features and integrations with external decentralised finance protocols. Occasionally, these features will require a new release of the core Enzyme contracts. Investors should be aware that at every new Enzyme release, Portfolio Managers can opt in to upgrade their product from the previous version to the new version. This process gives Portfolio Managers an opportunity to change their original product configurations (eg. fees, rule-sets, etc). Once the product configurations are updated and the Portfolio Manager has signaled their intent to migrate to the new Enzyme version, the Portfolio Manager is restricted from accessing the upgrade for 48 hours. This time period gives investors an opportunity to opt out of the product by redeeming their shares.